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Proliferative response of human and animal tumours to
surgical wounding of normal tissues: onset, duration
and inhibition
AE Bogden, J-P Moreau and PA Eden
Biomeasure Inc., Milford, MA 01757-3650, USA
Summary Acceleration of secondary tumour growth and metastases following excision of a primary tumour has been attributed to the
consequent removal of primary tumour-generated inhibitory factors. However, our studies have shown that surgical wounding of normal
tissues significantly stimulated the growth of malignant tissues without the concomitant presence or excision of a tumour mass. A humoral
stimulating component was indicated by the proliferative response of tumours and metastases distant from the surgical wound. All 16 human
and murine tumours, of nine different histologies, showed a measurable acceleration of growth when implanted in surgically treated animals,
suggesting that the ability of malignant tissue to respond to surgical wounding of normal tissue was not histologically or species specific. The
proliferative surge of malignant tissues was detectable soon after wounding and had a duration of 2-3 days. The surgical wound as the
source of the tumour-stimulating factor(s) was affirmed by the significant inhibition of tumour proliferative responses when a somatostatin
analogue was applied topically to the surgical wound within 1 h of wounding, and/or during the critical tumour-stimulatory period of 1-2 days
after wounding. A potential therapeutic window for reducing a risk factor that may be inadvertently imposed upon every surgical/oncology
patient is indicated.
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Inhibition of tumour growth by tumour mass is a phenomenon
recognized and repeatedly studied since the early 1900s (Ehrlich,
1908; Marie and Clunet, 1910; Tyzzer, 1913). Numerous reports,
summarized more recently by Keller (1983) and O'Reilly et al
(1994), have indicated that the presence of a primary tumour
inhibits the growth rate of metastases or of a second tumour
implant, and that removal or eradication of the primary tumour
accelerates growth at secondary sites. Early explanations for
apparent exacerbations ofdisease reflected Ehrlich's hypothesis of
'Athrepsia'; that any actively growing tumour removed certain
specific nutritive material necessary for growth from the host
animal (Ehrlich and Apolant, 1905). Subsequent explanations
stressed surgical relief from growth-limiting factors, such as
anatomical boundaries, anoxia and nutritional deficiencies, or that
the immunological relation between host and tumour was somehow
alteredby surgery,thereby facilitating tumourescape. However, the
underlying cause ofthe occasional explosive metastatic manifesta-
tion after resection of 'primary' malignancy remained in question.
An alternative explanation, proposed by Keller (1983), suggested
that soluble factors released by a tumour suppress the growth of
tumours in other sites. Once the primary tumour is removed, its
inhibitory influence is likewise abolished, permitting the
unchecked growth ofmetastatic cells. More recently, O'Reilly et al
(1994) demonstrated that inhibition of metastases by a primary
tumour was mediated, in part, by a circulating angiogenesis
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inhibitor (angiostatin). They postulated that a primary tumour,
while capable of stimulating angiogenesis in its own vascular bed
by generating angiogenic stimulators in excess of angiogenesis
inhibitors, the angiogenesis inhibitor, by virtue of its longer half-
life in the circulation, reaches the vascular bed of a secondary
tumour in excess of angiogenic stimulator escaping from the
primary tumour or generated by the secondary tumour. While there
is little question that, under the conditions hypothesized, excision
ofthe primary tumour would abrogate the tumour-inhibitory effect,
the role ofthe surgical wound, per se, in the phenomenon ofaccel-
erated growth of residual tumours and metastases following
surgical extirpation or debulking of a primary tumour mass has
been obscured by the interpretation that the proliferative response
was the consequence of eliminating primary tumour-generated
inhibitory factors.
There is now considerable evidence indicating that the overall
process of healing and repair of surgically damaged tissue,
including the necessary intercellular communication, is highly
regulated in humans and other animals by a number of specific,
soluble growth factors which are released within the wound envi-
ronment and which appear to induce neovascularization, leucocyte
chemotaxis, fibroblast proliferation, migration and deposition of
collagen and other extracellular matrix molecules within the
wounds. The growth factors that have been identified and isolated
are, typically, specialized soluble proteins or polypeptides
(McGrath, 1990; Ksander, 1989; Amento and Beck, 1991; Mustoe
et al, 1987; Lynch et al, 1989; Bennett and Schultz, 1993). Thus,
evidence of growth factors released at the site of trauma is exten-
sive. With a more complex description of the various growth
factors, it is increasingly apparent that the same mediators of cell
growth and stromal synthesis are involved in malignancy, fetal
growth and wound healing.
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Table 1 Proliferative response of human and animal tumours to surgical wounding of normal tissues
Tumour designation
Breast tumours
MX-1
R-3230AC
Prostate tumours
H-1579
PC-3
DU-145
11095
2PR121 (D)1 R
2PR121(D)1
Pancreatic tumours
MIA-PaCa
CAPAN-2 pancreatic
Miscellaneous tumours
B16-melanoma
WR-6 lymphoma
FCB bladder
MPC-11 myeloma
CX-1 colon
SWARM sarcoma
Species/strain of origin Site of tumour implanta Severity of traumab Percentage increased tumourweightc
Human
Rat, Fischer
Human
Human
Human
Rat, Fischer
Rat, Noble
Rat, Noble
Human
Human
Mouse, C 57BU6
Rat, Wistar-Furth
Mouse, C57BU6
Mouse, BALB/c
Human
Rat, Wistar-Furth
aHuman tumours were tested as s.c. xenografts implanted in athymic nude mice. bSeverity of trauma: +++, skin excision with abrasion; ++, skin excision; +,
Alzet pump implantation. cStatistically significant according to Student's t-test: *P< 0.05; **P< 0.01. Tumourweight in traumatized animal (test)/tumour weight in
non-traumatized animals (control) x 100
In our own studies, surgical traumatization (wounding) of
normal connective tissues, such as excision of a segment ofskin or
abrasion ofsubcutaneous fascia, induced a significant proliferative
response of human prostate tumour xenografts implanted in
athymic nude mice (Bogden et al, 1996). Application of a somato-
statin analogue, a neuroendocrine antisecretagogue, to the wound
had an inhibitory effect on the proliferative response, suggesting
the surgical wound as a source oftumour-stimulatory factors. Our
primary objective has been to document further the role of the
surgical wound, and thus to differentiate two phenomena: one that
focuses on the surgical wounding of normal tissues and the resul-
tant release oftumour-stimulating factors from the wound and the
other as defined by O'Reilley et al (1994), which focuses on the
surgical extirpation of a tumour mass and the coincident elimina-
tion of tumour-generated inhibitory factors. The feasibility of
inducing a therapeutic antiproliferative effect by treating the
surgical wound with a somatostatin analogue is demonstrated.
MATERIAL AND METHODS
Animals
Immunodeficient athymic nude mice (NCr-nu), used as recipients of
human tumour xenografts for serial transplantation and testing,
were received from Harlan, Madison, WI, USA, and housed in a
pathogen-free biocontainment facility Tumour donor and athymic
test animals were maintained ad libitum on an irradiated, Harlan
Teklad LM-485 mouse/rat diet. The immunocompetent three rat and
two mouse strains listed in Table 1, used as recipients of syngeneic
tumourgrafts, were maintained adlibitum on the standard Formulab
diet 5008. All procedures were performed in compliance with the
Guide forthe Care and use ofLaboratory Animals,NIH Publication
No. 86-23, revised 1985, and enhanced Standard Operating
Procedures on humane use and care of laboratory animals in a
pathogen-free barrier facility maintained at our laboratories.
Tumour sources
The PC-3 and DU-145 human prostate adenocarcinomas were
obtained from the American Type Culture Collection, Rockville,
MD, USA, as in vitro maintained cell culture systems. They were
adapted to in vivo transplantation in our laboratory. The H-1579
human prostate tumour was established in vivo transplantation
directly as a primary explant. This tumour, as well as all other
human and animal tumours used in this study, was obtained from
and maintained by the Breast Cancer Animal and Human Tumor
Bank, Biomeasure Inc., Milford, MA, USA. The Tumor Bank has
subsequently been transferred to the DCT Tumor Repository,
maintained as a service facility by the Biological Testing Branch,
Division of Cancer Treatment, National Cancer Institute,
Frederick Cancer Research and Development Center, Frederick,
MD, USA.
Tumour implantations
Both human and animal tumour systems were carried in serial
transplantation by subcutaneous (s.c.) implantation of a 2-3 mm3
mince into the right flank. Tumours were transplanted from donor
animals at the mid-log phase ofgrowth. Human tumours served as
xenografts in athymic nude mice and murine tumours were
implanted in their syngeneic strain of origin. Tumour grafts were
implanted directly into the trauma site under the suture lines
(intralesional) or in the flank contralateral to the surgical wound
when topical treatment was to be applied to the trauma. The 16
tumour lines included in this study are listed in Table 1. The
murine melanoma B16-FIO was selected as the initial experi-
mental test system because of its growth and morphological char-
acteristics resembling cutaneous melanoma. When implanted s.c.
or i.d. into athymic nude mice,black, cutaneous lesions are clearly
discernible within 3 days (Bogden et al, 1991). Cells injected i.v.
result in black, macroscopically visible metastases. An inoculum
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of 10 cells was used for implanting both C57BL/6 and athymic
nude female mice.
Tumours were measured two or three times weekly with Vernier
calipers and tumour weight (mg) was calculated from tumour
dimensions (mm x mm)following theformulaofaprolateellipsoid:
L x W2/2
Where L is the longer ofthe two measurements and the first value
recorded. Levels of statistical significance were determined with
Student's t-test.
Surgical trauma
Severity of surgical trauma varied in degree and is classified as
follows: + + +, skin excision with abrasion ofsubcutaneous fascia
at the surgical site; + +, skin excision only; and +, Alzet pump
implantation s.c.
Skin excision
A section ofskin, full thickness, approximately 12 mm in diameter
was excised from the right orleft flank under sterile conditions and
under light ether anaesthesia. Wound edges were immediately
approximated and closed with Michel clamps.
Skin excision with abrasion
A 12-mm-diameter, full-thickness skin graft was excised from the
right or left flank under sterile conditions. The raw graft bed was
then traumatized by abrading with a burred needle. Abrasion was
accomplished by carefully, but firmly, drawing the burred needle
the full length of the exposed subcutaneous tissues four times and
then again at right angles four times. Bleeding was minimal and
the surgical wound was immediately closed with Michel clamps.
Animals were anaesthetized with intraperitoneally (i.p.) adminis-
tered 4% chloral hydrate.
Lanreotide (LAN) treatment
Lanreotide (BIM-23014C, Somatuline) having the structure [D-j3-
Nal-Cys-Tyr-D-Trp-Lys-Val-Cys- Thr-NH2] acetate is along-acting
octapeptide analogue of somatostatin (SRIF), a neuroendocrine
antisecretagogue (Heiman et al, 1987). To enhance transdermal
delivery, it was administered at aconcentration of500[tg 0.05 ml-l
in either a 10%, 25% or50% dimethylsulphoxide (DMSO) - saline
vehicle. Treatment consisted ofa 0.05-ml drop applied topically to
the surgically treated area. Lanreotide (LAN) was then gently
rubbed onto the surgical area and around the wound clips for 1 min
with alatex-glovedfinger.The DMSO - saline vehicle was admin-
istered similarly.
Timing of assay endpoint
A comparison of tumour growth between test and control animals
was made afterallowing for the time required for a tumourprolifer-
ative response to be translated into a relative increase in tumour
mass.This sizedifference betweentumours,resulting fromthe same
size inocula implanted in intact and surgically wounded animals,
becomes evident during log phase of measurable tumour growth.
Since tumour lines differ in growth rate, timing of assay end point
differed between assays. A prerequisite is to implant the tumour
inocula during the critical 1-3 days after wounding. As the prolifer-
ative response occurs as a proliferative surge soon after wounding,
theresultantdifference in tumourmass,measurableduring logphase
ofgrowth,resembles that ofan initial difference in inoculum size.
Proliferative response of human and animal tumours to
surgical trauma
This study was, in essence, a screening of the proliferative
responses of human and animal tumours to acquire additional
experimental evidence concerning the histological and species
specificity of the wound-generated tumour-stimulatory factors.
Sixteen transplantable tumours ofnine different histologies and of
bothhuman and murine origin were implanted into surgically trau-
matized and non-traumatized animals. Although the severity ofthe
surgical wound varied in degree between assays, within each assay
grafts of identical size were implanted in both surgically trauma-
tized, as well as non-traumatized, hosts (Table 1). The percentage
increase in tumour weight in traumatized (test) over that in non-
traumatized (control) animals was determined during mid or log
phase ofgrowth as the percentage test/control x 100.
Determining the onset and duration of the proliferative
response of tumours to surgical trauma
The effect ofsurgical wounding ofnormal tissues on the growth of
B16-FlO cells implanted s.c. in athymic nude females was deter-
mined by excision of a full-thickness skin segment from the right
flank on day 0. On day 1, all animals were implanted with 105
Table 2 Onset and duration of the proliferative response of tumours to surgical trauma
Group no. Treatment Days after Tumour weighta Growth rate
Implant (mg) per day (mg)
1C No surgery control. Tumour implanted s.c., right flank, day 0 14 454 + 76 32.5
1 Surgery left flank, day 0. Tumour implanted s.c., right flank, day 0 14 1031 + 112b 73.6
2C No surgery control. Tumour implanted s.c., right flank, day 1 15 972 + 232 64.8
2 Surgery left flank, day 0. Tumour implanted s.c., right flank, day 1 15 1391 + 166 92.7
3C No surgery control. Tumour implanted s.c., right flank, day 2 14 813 + 268 58.1
3 Surgery left flank, day 0. Tumour implanted s.c., right flank, day 2 14 1333 + 244 95.2
4C No surgery control. Tumour implanted s.c., right flank day 3 15 950 ± 185 63.3
4 Surgery left flank, day 0. Tumour implanted s.c., right flank, day 3 15 764 ± 166 50.9
5C No surgery control. Tumour implanted s.c., right flank, day 4 14 448 ± 111 31.9
5 Surgery left flank, day 0. Tumour implanted s.c., right flank, day 4 14 558 ± 200 39.8
aData reported as means ± s.e.m. on ten animals per group. bSignificantly larger than non-traumatized control, P< 0.05.
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Table 3 Effects of trauma and lanreotide on seeding of blood-borne
metastases to the lung
Number of lung metastasesb
Group no. Lanreotide Animal category
treatment perioda
Traumatized Non-traumatized
1 Untreated control 97.3 ± 11.7 47.1 ±8.0c
2 Days-1 to8 19.6 ±5.3** 17.2+5.9*
3 Days 0-9 9.0 ± 4.9** 27.0 ± 3.6
4 Days1-10 59.8±11.5 44.2±14.3
5 Days 2-11 82.8 ± 10.9 46.9 ± 14.7
6 Days3-12 76.6±13.3 43.0±12.3
7 Days 4-13 82.4 ± 8.7 51.8 ± 13.0
8 Days 5-14 72.3 ± 11.0 51.3 ± 10.2
aLAN administered 500 mg per injection, s.c., b.i.d., q.d. bAnimals surgically
wounded on day -1. Melanoma cells injected i.v. on day 0. Data reported as
means ± s.e.m. on eight animals per group. Significantly different from
untreated control: **P<0.01; *P<0.05. cNon-traumatized group 1 significantly
fewer metastases than traumatized group 1, P<0.05.
B16-FIO melanoma cells in the right flank: group 1, non-surgi-
cally treated, was implanted s.c.; and group 2, surgically treated,
was implanted intralesionally. The assay was terminated andresul-
tant tumours measured on day 15 after implantation.
Forthefollowing study,tumourinoculawereimplanted s.c. inthe
flank opposite from the surgical lesion to limit tumour responses to
humoral factors (Table 2). One hundred athymic nude females were
randomized into ten groups often animals per group. Groups 1 to 5
were surgically traumatized in the morning of day 0 by the sterile
excision ofafull-thickness skin segmentfrom the left flank. Groups
IC to 5C were not surgically treated to serve as non-traumatized
controls. Groups IC and 1 were implanted with 105 B16-F10
melanoma cells s.c. in the right flank in the afternoon ofday 0, i.e.
4-6 h after wounding of group 1. Subsequently, groups 2C and 2
were implanted on day 1, groups 3C and 3 on day 2, groups 4C and
4 on day 3 and groups 5C and 5 on day 4 after wounding. Thus, the
surgically traumatized groups were paired with non-traumatized
controls as shown in Table 2. No other treatment was administered.
Although the experimental design required five tumour cell donor
animals during the five consecutive implantation days, traumatized
groups and theirnon-traumatized controls wereeach implanted with
tumour cells from the same donor. The assay was terminated by
euthanasia of traumatized and control groups at 14- and 15-day
intervals after tumour implantation. Each day of sacrifice was
identical for both the traumatized group and its corresponding non-
traumatized control group. Vernier caliper measurements of the
resultant s.c. tumours were made and tumour weights calculated.
Since the duration of the proliferative stimulus was the variable
being determined, the inoculum size (cell number) was maintained
as a constant.
Seeding of blood-borne metastases to the lung
The effect of surgical trauma and LAN treatment on the seeding
and growth of blood-borne metastases to the lung was determined
in C57BL/6 female mice implanted with the syngeneic B16-F1O
melanoma (Table 3). A total of 128 mice of the same age and sex
were randomized into 16 groups ofeight animals per group. In the
afternoon ofday -1,64 animals (eightgroups) were surgically trau-
matized with a full-thickness skin excision followed by abrasion of
the normal fascia in the raw skin bed. In the morning of day 0, all
traumatized animals plus 64 non-traumatized control animals, were
inoculated i.v. with 105 B16-FlO melanoma cells. Treatment with
LAN, 500 [.g per injection, in a saline vehicle s.c., b.i.d. for 10
days, was initiated at 1-day intervals beginning on day -1.
As shown in Table 3, the assay consisted of two animal cate-
gories, traumatized and non-traumatized, each consisting of eight
groups of animals. Group 1 in each category received no LAN
treatment, serving as untreated control animals. LAN treatment
was initiated with group 2 in each category in the morning of day
-1, i.e. a pretreatment administered approximately 5 h before the
surgical wounding ofanimals in the traumatized category and 24 h
before both categories were implanted i.v. with B16-FlO mela-
noma cells on day 0. Thereafter, LAN treatment ofgroups in each
category was initiated at 1 day intervals. Thus, all groups were
seeded i.v. with melanoma cells on the same day and all groups,
except for the untreated group 1 controls,received 10 days ofLAN
treatment. The assay was terminated on day 15 after wounding and
the number of macroscopically visible, melanotic lung metastases
in the excised lungs ofeach animal was determined.
Table 4 Inhibiting the proliferative response of tumours by treating the surgical wound: a therapeutic window after traumatization
Tumour weight (mg)a
Group Lanreotide H-1579 Percentage DU-145 Percentage MIA-PaCa2 Percentage MX-1 Percentage
no. treatment prostate prostate pancreas breast
day 27 T/C day 20 T/C day 18 T/C day 18 T/C
1 Untreated control 490 ± 52 - 201 ± 66 - 406 ± 74 - 423 ± 130 -
2 Traumatized only control 850 ± 69b 173 442 ± 98c 220 695 ± 142c 171 652 ± 104 154
3 1 h after trauma, dayO 560 ± 68d 361 ± 122 82 602±171 148 278 ± 68e (A
4 1 h aftertrauma+day 1, b.i.d. 673 ± 77 79 320 ± 104 72 329±64e 632 ± 178 97
5 1 h aftertrauma+days 1 and 2, b.i.d. 726± 103 85 158±27e i) 497 ± 169 72 546 ± 71 84
6 1 h after trauma + days 1, 2 and 3, b.i.d. 852 ± 174 100 313 ± 136 70 477 ± 69 69 580 ± 148 89
7 1 h after trauma + days 1, 2, 3 and 4, b.i.d. 673 ± 87 79 302 ± 50 68
aData reported as means ± s.e.m. on eight animals per group. Percentage T/C, percentagetestcontrol x 100. Encircled numbers indicate the nadir of the
proliferative response. bSignificantly different from group 1, P< 0.001. cSignificantly different from group 1, P< 0.05. dSignificantly different from group 2,
P< 0.01. eSignificantly different from group 2, P< 0.05.
British Journal ofCancer (1997) 75(7), 1021-1027 0CancerResearchCampaign 1997Tumourproliferative response to surgical wounding 1025
Inhibiting the proliferative response of tumours to
trauma by treating the surgical wound
To confirm that the release of tumour-proliferative factors at the
site of surgical trauma occurs soon after wounding and has a time-
defined limit of 2-3 days, four human tumours, the H-1579
prostate, MX- I breast, MIAPaCa-2 pancreas and DU-145 prostate,
were treated in the same experimental design (Table 4). Tumour
xenografts were implanted s.c. in the right flank of athymic nude
mice in the morning of day 0. Surgical trauma to the left flank, i.e.
excision ofa full-thickness (1-cm diameter) skin segment followed
by light abrasion of the raw skin bed, was induced in the afternoon
of the same day, i.e. in approximately 3-4 h after tumour implanta-
tion. Each tumour system, composed of six to seven groups of
eight animals per group, had a tumoured, LAN-untreated, non-
traumatized, control group I and a tumoured, LAN-untreated,
traumiiatized, control group 2. Initial topical application of LAN to
the wound area was administered to groups 3-7 1 h after surgery,
group 3 animals receiving only the one treatment. Subsequent,
2000 -
P<0t001
additional treatments of groups 4-7 were administered on days 1,
2, 3 and 4 after wounding in a b.i.d. regimen. LAN was applied
topically at a concentration of 500 Ltg 0.05 ml in a 10%
DMSO-saline vehicle.
RESULTS
The proliferative response of human and animal
tumours to surgical wounding of normal tissues
Table conmpares the proliferative responses of 16 transplantable
tumours of nine different histologies and of both human and
murine origin, when implanted into surgically traumatized and
non-traumatized animals. All tumours, whether implanted directly
into the surgical wound or distant from the wound, i.e. in the oppo-
site flank, were larger in surgically treated animals. Although
surgical site implantation resulted in the most rapid tumour
growth, humoral tumour-stimulatory factors are indicated by the
proliferative response of tumours implanted distant (opposite
flank) from the wound. Human tumour zenografts implanted into
traumatized athymic nude mice were also significantly stimulated
suggesting that the tumour-stimulatory factors are not species
specific.
Onset and duration of the proliferative response of
tumours to surgical wounding
Sensitivity ofthe B 16-FIO melanoma to surgical wound-generated
stimulatory factors is illustrated by the relative tumour weights on
day 15 after implantation (Figure 1). Tumour cells implanted in the
surgical wound grew at a rate almost three times faster than that of
the same size inoculum implanted in non-traumatized animals. In
the following study, B16-F O cells were implanted s.c. in the flank
opposite to the surgical wound to determine tumour responses to
wound-generated humoral factors.
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Figure 1 Tumour-proliferative effect of surgical trauma as illustrated by the
relative tumour weights on day 15 after implantation of Bl 6-Fl 0 melanoma
cells s.c. in non-traumatized group 1 (U) and traumatized group 2(U) animals
I I T
0 1 2 3
Tumour implant day after surgery
4
Figure 2 Duration of the tumour-proliferative response to surgical trauma.
Tumour growth rate per day (mg) in traumatized animals (0) implanted on
day 0, 1, 2, 3 and 4 after traumatization. Tumour growth rate per day (mg) in
non-traumatized control animals is shown as the mean of all control values
(-) + s.d.(----)
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Onset and duration of the proliferative response of s.c.
implanted tumours to surgical wounding is summarized in terms
of tumour weight and growth rate per day in Table 2. The same
tumour inocula implanted in surgically wounded animals resulted
in larger s.c. tumours than in non-wounded animals, when tumour
inocula wereimplantedduring the first 2days afterwounding. The
greatest difference inproliferative response occurred with tumours
implanted on the same day as wounding, e.g. group 1 vs IC
(P < 0.05). The rate of tumour growth in traumatized animals
implanted on days 3 and 4 after wounding did not differ from
their non-traumatized control animals (Figure 2). The tumour-
proliferative effect was induced soon afterwounding (< 1 day) and
had a duration of approximately 2 days. Since tumours had been
implanted distant from the surgical wound (opposite flank), it
would suggest that this assay was detecting the activity of trauma-
generated humoral factors.
Effect ofsurgical trauma and lanreotide on seeding of
blood-borne metastases to the lung
Clinical studies have suggested that malignant cells, shed during
surgical procedures involving tumourdebulking or excisions, e.g.
prostatectomy, may seed the surgical bed and could beresponsible
for some instances of local tumour recurrence (Kassabian et al,
1993; Turnbull et al, 1967). This study was designed to determine
(1) the effect ofsurgical wounding on the seeding ofblood-borne
metastases; and (2) whether the systemic administration of LAN
during the critical tumour-proliferative period 1-2 days after
wounding would inhibit seeding of the blood-borne metastases.
The results are summarized in Table 3.
Intravenous implantation of 105 B16-FIO cells in surgically
wounded, untreated control animals induced an average of 97.3 +
11.7 macroscopically countable lung metastases by day 15 after
implant. The same inoculum in non-wounded, untreated control
animals resulted in an average of only 47.1 ± 8.0 metastases,
significantly (P < 0.05) fewer. LAN treatment initiated on day -1
as an initial pretreatment administered 5 h before surgical
wounding and 24 h before tumour cell implantation (group 2)
induced an 80% reduction in the number of lung metastases in
surgically wounded animals (P <0.01) compared with a 63%
reduction in non-traumatized animals (P <0.05). LAN treatment
initiated on day 0, the day of tumour implantation, and 24 h after
wounding (group 3) induced a 91% reduction in the number
of lung metastases in surgically wounded animals (P <0.01)
compared with a 43% reduction in non-traumatized animals. LAN
treatment initiated on day 1 or later after wounding (groups 4-8)
had no significant inhibitory effects on the seeding or growth of
lung metastases in either traumatized or non-traumatized animals.
Inhibiting the proliferative response of tumours to
trauma-associated tumour-stimulatory factors by
treating thesurgical wound: defining a therapeutic
window
Our studies had indicated that the surgical trauma-associated,
tumour proliferative factor(s) are released soon after wounding,
having a duration of approximately 2-3 days. We had also
observed that LANappliedtopically to thesurgical wound appears
to inhibit the release of these factors, inducing a therapeutic
tumour-inhibitory effect in surgically treated animals (Bogden et
al, 1996). The following studies were designed to confirm the
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findings described above and to test the antisecretagogue activity
ofLAN furtherby treating the surgical wound only during the crit-
ical first 2-3 days aftertraumatization. The initial treatment onday
0 was administered within 1 h ofwounding. Four human tumours,
the MX-1 breast,H-1579 prostate,MIA-PaCa-2 pancreas and DU-
145 prostate, were tested in the same experimental design for
further confirmation (Table 4).
All tumours implanted in traumatized, untreated control groups
(group 2) showed an enhanced growth when compared with
tumours implanted in their respective non-traumatized, untreated
controls (group 1). MX-1 breast tumour, showing the lowest
proliferative response to trauma, had the tumour-stimulatory effect
significantly (P <0.05) inhibited by a single topical application of
LAN. Accelerated growth ofthe H-1579 prostate tumour was also
significantly (P < 0.01) inhibited by a single application of LAN.
MIA-PaCa-2 pancreatic tumour required additional treatments of
the trauma site on day 1, and the DU-145 prostate tumourrequired
additional treatments on days 1 and 2 to induce a significant (P <
0.05) inhibition of the tumour-stimulatory effect. Importantly,
although two tumours required more than a single application of
LAN to the wound site, all tumours exhibited a significant nadir of
the proliferative response within the first 2-3 days afterwounding.
Additional treatment beyond this critical period did not further
enhance the tumour-inhibitory effects, suggesting a potential ther-
apeutic window of 1-3 days for the effective application of a
somatostatin analogue.
DISCUSSION
That tumour growth-stimulating factors can be generated by
simple surgical wounding of normal connective tissues reinforces
the role of the surgical wound in the phenomenon of accelerated
growth of residual tumours and metastases following surgical
extirpation or debulking of a primary tumour mass. The ability of
malignant tissues to respond is apparently not an histologically
limiting characteristic, as all tumours tested were responsive to
surgical wounding. There is also no evidence that wound-gener-
ated tumour-stimulating factors are species specific. Both human
and animal tumours had an increased rate of growth in surgically
traumatized animals. Critical to this phenomenon is the evidence
that the tumour-stimulating factors have a humoral component, as
evidenced by the proliferative response of tumours distant from
the surgical wound.
The relevance ofthis phenomenon to cancer treatment isempha-
sized by the fact that tumour proliferation is a risk factor that may
be imposed upon every surgical/oncology patient to some degree.
Cytoreductive surgery as an adjuvant treatment for patients whose
disease is believed to be too extensive for cure by either drugs or
surgery alone is an acceptable and widely used therapeutic
modality. Our experimental systems have concentrated on human
and animal tumours of the breast and prostate, malignancies in
which stimulation of in situ malignant tissue or distant metastases
as a result of surgical trauma may be clinically inadvertent. For
example, transurethral resections ofthe prostate in benignprostatic
hyperplasia and excisional biopsies (lumpectomies) of the breast
are conditions in which surgical trauma may precede histological
evidence of the presence or absence of in situ cancer and metas-
tases, and may possibly exacerbate an essentially latent disease.
The primary objective of applying a somatostatin analogue
(LAN) as an endocrine antisecretagogue to the wound was to
confirm thatthetumour-proliferativefactors were woundgenerated.
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Although delivery of the analogue was transdermal, and thus in all
likelihood suboptimal, direct access of the antisecretagogue to the
relevant secretory mechanisms in high concentrations may have
been facilitated by evading systemic dilution and hepatic pass-
through effects. Since the release of tumour growth-stimulatory
factors occurs early and is constrained to the 2 or 3 days after
wounding, as shown in the paradigm used, the same tumour-
inhibitory effect might be obtained as a therapeutic endeavour by
inserting a short-term, sustained release, somatostatin preparation
into the surgical wound, or perhaps, by a simple powdering of
wound surfaces with a suitable analogue before wound closure. No
attempt has been made to optimize doses or treatment regimens in
these studies. Nor has it been within the scope of these studies to
identify the various soluble tumour growth factors generated within
the wound environment for the healing and repair of surgically
damaged normal tissues. The primary objective was to document
and define the phenomenon of the surgical wound further as a
significant source oftumour-stimulating factors.
The feasibility of inducing a therapeutic tumour-inhibitory
effect by inhibiting the phenomenon with a somatostatin analogue
augers for a post-operative treatment modality as wound breaking
strength assays indicate that somatostatin analogues do not signifi-
cantly affect wound healing in normal rats (Abribat et al, 1992;
Bogden et al, 1996).
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